Amblyomin-X

Drug Profile

Amblyomin-X

Latest Information Update: 29 Apr 2017

Price : $50

At a glance

  • Originator Uniao Quimica Farmaceutica
  • Class Antineoplastics
  • Mechanism of Action Apoptosis stimulants; Factor Xa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 25 Apr 2017 União Química Farmacêutica Nacional plans a phase I trial for Solid tumours (Second-line therapy or greater) in Brazil (NCT03120130)
  • 29 Mar 2017 Preclinical trials in Solid tumours in Brazil (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top